Previous 10 | Next 10 |
Gainers: Redbox Entertainment (RDBX) +48%. Blue Apron Holdings (APRN) +36%. Accolade (ACCD) +28%. Forge Global Holdings (FRGE) +22%. Hilltop Holdings (HTH) +19%. The Oncology Institute (TOI) +18%. OppFi (OPFI) +18%. Seer (SEER) +16%. Companhia Energetica de Minas Gerais (CIG) +16%. Silk Road ...
Stocks plunged on Friday, hurt by a negative reaction to the latest round of tech earnings, with Amazon posting its biggest single-day loss in more than 15 years. The Nasdaq led the decline, falling 4.2% and recording its worst monthly performance since the Financial Crisis. Even amid a wash ...
The following slide deck was published by Accolade, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Accolade, Inc. 2022 Q4 - Results - Earnings Call Presentation
Gainers: GTY Technology Holdings (GTYH) +114%. Vaxxinity (VAXX) +57%. Zymeworks (ZYME) +35%. Redbox Entertainment (RDBX) +33%. Finch Therapeutics Group (FNCH) +29%. Opiant Pharmaceuticals (OPNT) +29%. Puyi (PUYI) +27%. Cyngn (CYN) +24%. Clearwater (CLW) +24%. Anixa Biosciences (ANIX) +21%. Lo...
Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...
Accolade (ACCD) -41% on Q4 earnings release. Sono Group (SEV) -12% on pricing $10M follow-on share offering. Robinhood Markets (HOOD) -10% on Q1 earnings release. Amazon.com (AMZN) -10% on Q1 earnings release. The Western Union (WU) -9% o...
Image source: The Motley Fool. Accolade, Inc. (NASDAQ: ACCD) Q4 2022 Earnings Call Apr 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Accolade, Inc. (ACCD) Q4 2022 Earnings Call Transcript
Accolade, Inc. (ACCD) Q4 2022 Earnings Conference Call April 28, 2022, 04:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Medical Officer Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Bla...
Accolade (NASDAQ:ACCD) stock sank 30% postmarket on Thursday after the healthcare firm reported Q4 results and provided disappointing outlook. Q4 GAAP EPS was -$0.51 vs. -$0.09 in Q4 2021 as operating expenses more than doubled Y/Y to ~$80M. Additionally, CEO Rajeev Singh said a large custome...
Accolade press release (NASDAQ:ACCD): Q4 GAAP EPS of -$0.51 misses by $0.12. Revenue of $93.76M (+58.4% Y/Y) beats by $2.18M. Shares -30.38%. For further details see: Accolade GAAP EPS of -$0.51 misses by $0.12, revenue of $93.76M beats by $2.18M
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...